Use of a traditional Chinese medicine composition in preparing a drug for treating depression

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and in particular to a Chinese medicine composition for treating depression. The Chinese medicine composition is mainly prepared from astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, kudzu root, angelica, salvia miltiorrhiza, honeysuckle, seaweed, kelp, oyster, and immature bitter orange. The Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, improve the symptoms of loss of interest in depression model rats, effectively alleviate the symptoms of increased inflammatory factors TNF-α, IL-1β, and INF-γ caused by depression, significantly increase the levels of 5-hydroxytryptamine and dopamine in rat cortex and hippocampus, and effectively treat depression.

Description

Technical Field

[0001] The present invention relates to a traditional Chinese medicine composition and application thereof, in particular to a traditional Chinese medicine composition and application thereof in preparing a medicine for treating depression, belonging to the technical field of traditional Chinese medicine. Background Art

[0002] Depression is the most common depressive disorder, characterized by a pronounced and persistent low mood. It is the primary type of mood disorder. Clinically, the depressed mood is disproportionate to the individual's situation, ranging from melancholy to profound grief, low self-esteem, depression, and even pessimism and world-weariness. Suicidal attempts or behaviors may occur, and even catatonia may occur. Some cases present with significant anxiety and motor agitation. In severe cases, psychotic symptoms such as hallucinations and delusions may develop. Each episode lasts for at least two weeks, and in some cases, even for several years. Most cases tend to relapse. While most episodes resolve, some may have residual symptoms or become chronic.

[0003] Traditional Chinese medicine explains depression as "depression" (also known as depression disease), which is caused by the original liver being hyperactive or the physical constitution being weak, coupled with emotional damage, which leads to stagnation of qi, liver failure to release, spleen failure to function properly, heart failure to nourish, and imbalance of yin and yang qi and blood in the internal organs. It is a type of disease with depression, restlessness, chest fullness and stuffiness, bloating and pain in the ribs, or irritability and crying, or a foreign body obstruction in the throat as the main clinical manifestations.

[0004] Xintong Oral Liquid can invigorate Qi and activate blood circulation, resolve phlegm and unclog the meridians. It is used for chest pain caused by Qi and Yin deficiency and phlegm and blood stasis, with symptoms including heart pain, chest tightness, shortness of breath, nausea, and poor appetite; it is also used for angina pectoris caused by coronary heart disease. Currently, there are no reports on the effectiveness of Xintong Oral Liquid in treating depression. Currently, depression is primarily treated with Western medicine, but patients can easily develop dependence on medications, and Western medicines have significant side effects, such as headaches, dry mouth, nausea, and liver and kidney dysfunction. Summary of the Invention

[0005] This invention further develops the uses of the existing product, "Xintong Oral Liquid." This new use stems from clinical feedback: some patients with depression experienced unexpected improvements in their depression symptoms while taking "Xintong Oral Liquid" to treat coronary heart disease and angina pectoris. Based on this clinical feedback, the applicant has conducted further research on the use of "Xintong Oral Liquid" in treating depression.

[0006] The first object of the present invention is to provide a traditional Chinese medicine composition that can be used to treat depression, the traditional Chinese medicine composition comprising astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, kudzu root, angelica, salvia miltiorrhiza, honeysuckle, seaweed, kelp, oyster, and immature bitter orange;

[0007] The specific ratio of the raw materials included in the Chinese medicine composition is:

[0008] 150-200 parts by weight of Astragalus root; 60-120 parts by weight of Codonopsis pilosula; 40-90 parts by weight of Ophiopogon japonicus

[0009] 35-80 parts by weight of Polygonum multiflorum, 35-80 parts by weight of Epimedium, 120-170 parts by weight of Pueraria root

[0010] 35-80 parts by weight of Chinese Angelica sinensis, 80-120 parts by weight of Salvia miltiorrhiza, 35-80 parts by weight of Gleditsia sinensis

[0011] 60-120 parts by weight of seaweed 60-120 parts by weight of kelp 60-120 parts by weight of oyster 5-50 parts by weight of Citrus aurantium

[0012] Preferably,

[0013] 173 parts by weight of Astragalus root, 93 parts by weight of Codonopsis pilosula, 67 parts by weight of Ophiopogon japonicus, 53 parts by weight of Polygonum multiflorum

[0014] 53 parts by weight of Epimedium, 147 parts by weight of Puerariae Radix, 53 parts by weight of Angelicae Sinensis, 100 parts by weight of Salviae Miltiorrhiza

[0015] 53 parts by weight of Gleditsia spinosa, 93 parts by weight of seaweed, 93 parts by weight of kelp, 93 parts by weight of oyster, 27 parts by weight of Citrus aurantium.

[0016] The depression described in the present invention includes endogenous depression, reactive depression, latent depression, secondary depression induced by drugs, secondary depression caused by physical diseases, psychotic depression, manic depression, postpartum depression, menopausal depression, senile depression, atypical depression, seasonal depression, depression characterized by learning difficulties, and white-collar depression.

[0017] Furthermore, the depression may be caused by one or more of biological factors, psychological factors, drug factors, environmental factors, stress factors, and physiological factors; the biological factors include genetics, neurochemistry, neuroendocrine, and neural regeneration.

[0018] Specifically, the symptoms of depression include but are not limited to low mood, slow thinking, decreased volitional activity, cognitive impairment, and physical symptoms; the physical symptoms include but are not limited to sleep disorders, fatigue, changes in appetite, weight changes, constipation, pain in any part of the body, decreased libido, impotence, amenorrhea, nausea, vomiting, palpitations, chest tightness, sweating, and autonomic dysfunction.

[0019] The second object of the present invention is to provide a use of a traditional Chinese medicine composition in preparing a medicine for treating complications of depression.

[0020] Specifically, the complications of depression include anxiety, obsessive-compulsive disorder, sleep disorders, and physical discomfort; the physical discomfort includes headache, dizziness, palpitations, nausea and vomiting, memory loss, illusions and hallucinations, neurasthenia, constipation, pain in any part of the body, loss of libido, impotence, amenorrhea, chest tightness, sweating, and autonomic dysfunction.

[0021] The third object of the present invention is to provide a preparation prepared from a Chinese medicine composition and pharmaceutically acceptable excipients.

[0022] Specifically, the preparations include oral liquid, granules, tablets, capsules, pills, powders, granules, syrups, microcapsules, and ointments.

[0023] The fourth object of the present invention is to provide a method for preparing a Chinese medicine preparation.

[0024] The preparation method of the preparation is specifically as follows: taking Pueraria root and Salvia miltiorrhiza, adding 70% ethanol and heating under reflux twice, each time for 1 hour, combining the ethanol extracts and setting aside; adding water to the medicinal residues and astragalus, Codonopsis pilosula, Ophiopogon japonicus, Polygonum multiflorum, Epimedium, Angelica sinensis, Gleditsia sinensis, Sargassum, Laminaria japonica, Oyster, and Citrus aurantium immaturum, decocting twice, the first time for 2 hours and the second time for 1.5 hours, combining the decoctions, filtering, concentrating the filtrate to 1000 ml, combining the decoctions with the ethanol extracts, adding appropriate amount of ethanol to make the alcohol content reach 65%, refrigerating for 24-48 hours, filtering, recovering ethanol from the filtrate and concentrating it to 870 ml, refrigerating for 24-48 hours, filtering, adding 210 g of syrup, adjusting the pH value to 7.0 with 20% sodium hydroxide solution, adding water to 1000 ml, stirring evenly, filtering, and preparing according to conventional processes.

[0025] The present invention also provides use of the Xintong oral liquid prepared from the above-mentioned Chinese medicine composition in treating depression and its complications.

[0026] Compared with the prior art, the present invention has achieved remarkable technical effects:

[0027] (1) The Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, and improve the symptoms of loss of interest in depression model rats;

[0028] (2) The Chinese medicine composition of the present invention can effectively alleviate the symptoms of elevated inflammatory factors TNF-α, IL-1β, and INF-γ caused by depression;

[0029] (3) The Chinese medicine composition of the present invention can significantly increase the levels of 5-hydroxytryptamine and dopamine in the cortex and hippocampus of rats, and effectively treat depression. DETAILED DESCRIPTION

[0030] In order to make the purpose and technical solution of the present invention more clearly understood, the contents of the present invention are further described in detail by way of examples, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following examples. Without departing from the above technical premise of the present invention, corresponding replacements or modifications made according to common technical knowledge and customary means in the field are all included in the present invention.

[0031] Example 1 Oral Liquid Preparation

[0032] prescription:

[0033] Astragalus 173g, Codonopsis pilosula 93g, Ophiopogon japonicus 67g, Polygonum multiflorum 53g

[0034] Epimedium 53g, Pueraria lobata 147g, Chinese angelica 53g, Salvia miltiorrhiza 100g

[0035] Soapberry thorn 53g seaweed 93g kelp 93g oyster 93g Citrus aurantium 27g;

[0036] Preparation method:

[0037] Take Pueraria root and Salvia miltiorrhiza, add 70% ethanol and heat under reflux twice, each time for 1 hour, combine the ethanol extracts and set aside; the medicinal residues and Astragalus, Codonopsis, Ophiopogon, Polygonum multiflorum, Epimedium, Angelica, Gleditsia thorn, Sargassum, Kelp, Oyster, and Citrus aurantium are decocted in water twice, the first time for 2 hours and the second time for 1.5 hours, the decoctions are combined, filtered, and the filtrate is concentrated to 1000ml, combined with the ethanol extract, and an appropriate amount of ethanol is added to make the alcohol content reach 65%. The extract is refrigerated for 24-48 hours, filtered, and the filtrate is recovered and concentrated to 870ml. The extract is refrigerated for 24-48 hours, filtered, 210g of syrup is added, the pH value is adjusted to 7.0 with 20% sodium hydroxide solution, water is added to 1000ml, stirred well, and filtered to obtain the product.

[0038] Example 2 Oral Liquid Preparation

[0039] prescription:

[0040] Astragalus 150g, Codonopsis pilosula 60g, Ophiopogon japonicus 40g, Polygonum multiflorum 35g

[0041] Epimedium 35g, Pueraria lobata 120g, Chinese angelica 35g, Salvia miltiorrhiza 80g

[0042] 35g of Soapberry Thorn, 60g of Seaweed, 60g of Kelp, 60g of Oyster, 5g of Citrus aurantium

[0043] Preparation method: same as Example 1.

[0044] Example 3 Oral Liquid Preparation

[0045] prescription:

[0046] Astragalus 200g, Codonopsis 120g, Ophiopogon 90g, Polygonum multiflorum 80g

[0047] Epimedium 80g, Pueraria lobata 170g, Chinese angelica 80g, Salvia miltiorrhiza 120g

[0048] 80g of Soapberry Thorn, 120g of Seaweed, 120g of Kelp, 120g of Oyster, 50g of Citrus aurantium

[0049] Preparation method: same as Example 1.

[0050] Example 4 Granule Preparation

[0051] prescription:

[0052] Astragalus 173g, Codonopsis pilosula 93g, Ophiopogon japonicus 67g, Polygonum multiflorum 53g

[0053] Epimedium 53g, Pueraria lobata 147g, Chinese angelica 53g, Salvia miltiorrhiza 100g

[0054] 53g of Soapberry Thorn, 93g of Seaweed, 93g of Kelp, 93g of Oyster, 27g of Citrus aurantium;

[0055] Preparation method:

[0056] Take Pueraria root and Salvia miltiorrhiza, add 70% ethanol and heat under reflux twice, each time for 1 hour, combine the ethanol extracts and set aside; the medicinal residues and Astragalus, Codonopsis, Ophiopogon, Polygonum multiflorum, Epimedium, Angelica, Gleditsia thorn, Sargassum, Kelp, Oyster, and Citrus aurantium are decocted in water twice, the first time for 2 hours and the second time for 1.5 hours, the decoctions are combined, filtered, and the filtrate is concentrated to 1000 ml, combined with the ethanol extract, and an appropriate amount of ethanol is added to make the alcohol content reach 65%. The product is refrigerated for 24-48 hours, filtered, and the filtrate is recovered and concentrated to 870 ml. The product is refrigerated for 24-48 hours, filtered, 210 g of syrup is added, and the pH value is adjusted to 7.0 with 20% sodium hydroxide solution. The product is stirred, filtered, dried, and mixed to form granules.

[0057] Example 5 Capsule Preparation

[0058] prescription:

[0059] Astragalus 173g, Codonopsis pilosula 93g, Ophiopogon japonicus 67g, Polygonum multiflorum 53g

[0060] Epimedium 53g, Pueraria lobata 147g, Chinese angelica 53g, Salvia miltiorrhiza 100g

[0061] 53g of Soapberry Thorn, 93g of Seaweed, 93g of Kelp, 93g of Oyster, 27g of Citrus aurantium;

[0062] Preparation method:

[0063] Take kudzu root and salvia miltiorrhiza, add 70% ethanol, heat and reflux twice, each time for 1 hour, combine the ethanol extracts and set aside; the medicinal residues and astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, angelica, honey lonicera, seaweed, kelp, oyster, and immature bitter orange are decocted in water twice, the first time for 2 hours and the second time for 1.5 hours, the decoctions are combined, filtered, the filtrate is concentrated to 1000 ml, combined with the ethanol extract, and an appropriate amount of ethanol is added to make the alcohol content reach 65%. The product is refrigerated for 24-48 hours, filtered, the filtrate is recovered and concentrated to 870 ml, refrigerated for 24-48 hours, filtered, 210 g of syrup is added, the pH value is adjusted to 7.0 with 20% sodium hydroxide solution, stirred evenly, filtered, dried, crushed, and encapsulated to obtain the product.

[0064] Example 6 Tablet Preparation

[0065] prescription:

[0066] Astragalus 173g, Codonopsis pilosula 93g, Ophiopogon japonicus 67g, Polygonum multiflorum 53g

[0067] Epimedium 53g, Pueraria lobata 147g, Chinese angelica 53g, Salvia miltiorrhiza 100g

[0068] 53g of Soapberry Thorn, 93g of Seaweed, 93g of Kelp, 93g of Oyster, 27g of Citrus aurantium;

[0069] Preparation method:

[0070] Take kudzu root and salvia miltiorrhiza, add 70% ethanol, heat and reflux twice, each time for 1 hour, combine the ethanol extracts and set aside; the medicinal residues and astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, angelica, honey lonicera, seaweed, kelp, oyster, and immature bitter orange are decocted in water twice, the first time for 2 hours and the second time for 1.5 hours, the decoctions are combined, filtered, the filtrate is concentrated to 1000ml, combined with the ethanol extract, and an appropriate amount of ethanol is added to make the alcohol content reach 65%, refrigerated for 24-48 hours, filtered, the filtrate is recovered and concentrated to 870ml, refrigerated for 24-48 hours, filtered, 210g of syrup is added, the pH value is adjusted to 7.0 with 20% sodium hydroxide solution, stirred evenly, filtered, dried, mixed evenly to form granules, added an appropriate amount of auxiliary materials, mixed evenly, and tableted to obtain the product.

[0071] Pharmacological experiments

[0072] The inventors conducted relevant pharmacodynamic studies to demonstrate the efficacy of the Chinese medicine composition of the present invention in treating depression. It should be noted that the following experimental studies were all conducted on the basis of the safety of the drugs demonstrated by acute toxicity tests and long-term toxicity tests, and the dosages administered in the experimental studies were all within the safe dose range. The drugs selected for the following pharmacodynamic tests are drugs obtained by the representative formulas, dosage forms and preparation methods of the present invention; the inventors also conducted pharmacodynamic experiments on drugs obtained by other formulas, dosage forms and preparation methods included in the present invention. The experimental results show that drugs obtained by other formulas, dosage forms and preparation methods have the same or similar effects, but due to space limitations, they are not listed here one by one.

[0073] In addition, the following pharmacodynamic experiments only use some animal models as examples to verify the efficacy of the present invention. Here, only the pharmacodynamic experimental results of the traditional Chinese medicine composition of the present invention in treating depression, a mental illness, are shown. The inventors have also conducted relevant pharmacodynamic experiments on depression of other types and other pathogenic factors mentioned in the present invention, as well as on complications of depression. The experimental results show that they have the same or similar effects, and the pharmacodynamic experimental results are no longer listed one by one.

[0074] 1. Materials

[0075] 1.1 Experimental drugs and reagents

[0076] 1.1.1 Medication

[0077] The oral liquids obtained in Examples 1, 2, and 3 of the present invention;

[0078] Moclobemide tablets (National Medicine Approval No. H20030145, Lunan Beite Pharmaceutical Co., Ltd.);

[0079] Yangxinshi Tablets (National Medicine Approval No. Z37021102)

[0080] 5-HT, dopamine (ELISA) kit;

[0081] Rat tumor necrosis factor α (TNF-α), rat IL-1β, rat INF-γ interferon kit.

[0082] 1.1.2 Dosage

[0083] Example 1 Oral solution: 1.80 ml / kg (low dose), 3.60 ml / kg (medium dose), 7.20 ml / kg (high dose);

[0084] Example 2 Oral solution: 3.60 ml / kg;

[0085] Example 3 Oral solution: 3.60 ml / kg;

[0086] Moclobemide tablets: 0.036g / kg;

[0087] Yangxinshi tablets: 0.21g / kg.

[0088] 1.2 Experimental animals

[0089] SD rats, SPF grade, 180-220 g, experimental animal license number: SYXK(Lu)20180008, provided by Lunan Pharmaceutical Group Co., Ltd., were adaptively fed for 1 week before the experiment.

[0090] 2. Methods

[0091] 2.1 Experimental Animal Grouping

[0092] 90 SD rats were randomly divided into a model group, a blank group, moclobemide tablets, Yangxinshi tablets, three dose groups (high, medium, and low) of Example 1, Example 2 group, and Example 3 group, with 10 rats in each group.

[0093] 2.2 Establishment of CUMS depression model

[0094] Eight groups were established, including the model group, moclobemide tablets, Yangxinshi tablets, three dose groups of Example 1 (high, medium, and low), Example 2, and Example 3. The model was established according to the method of Reference (Lu SH, Guo J, Cai C, et al. Effects of Kaixin Powder onexpression of 5-HT receptor in hippocampus of depressed rats induced by CUMS[J]. Chin Herb Med, 2015, 7(2): 150-154.). Rats were housed in single cages and randomly received the following two different stress stimuli every day. The same stimulus could not appear continuously, so that the rats could not anticipate which stimulus would be used and avoid adaptation. The CUMS stimulation factors included: restraint for 2 hours; ice-water platform for 2 hours; noise stimulation (110 dB, 30 minutes); foot shock (4 mA, 50 times, 5 seconds between each shock); light stimulation (100,000 lx, 30 minutes); day / night reversal for 24 hours; moist bedding for 12 hours; and tail clamp (approximately 1 cm from the tip of the tail, 2 minutes). The model was maintained for 4 weeks, and body weight, sugar water consumption, and open-box horizontal and vertical movement scores of the rats were measured weekly. All 80 rats were successfully modeled, and the control group was fed normally.

[0095] 2.3 Administration

[0096] The rats in each treatment group were given corresponding drugs by gavage, and the rats in the blank group and model group were given an equal amount of normal saline by gavage, once a day for 21 days.

[0097] 3 Observation indicators

[0098] 3.1 Effects of rat behavior

[0099] 3.1.1 Changes in body mass

[0100] The body weight of the rats was measured on the 0th, 7th, 14th and 21st days of the experiment, and the body weight increase of the rats in each group was calculated.

[0101] Mass increase = (mass of the 21st celestial body - mass of the 0th celestial body) / mass of the 0th celestial body

[0102] 3.1.2 Sugar water consumption experiment

[0103] The sugar consumption test is a standard for assessing anhedonia, a core symptom of depression in animal models. Three days before the experiment, animals were acclimated to sugar. On the first day, two bottles of 1% sucrose solution were placed in the cage for 24 hours. On the second day, one bottle of 1% sucrose solution and one bottle of pure water were placed in the cage for 24 hours, with the water bottles swapped in the morning and afternoon. On the third day, the animals were deprived of food and water for 24 hours. During the actual experiment, one bottle of 1% sucrose solution and one bottle of pure water were placed in the cage, with the water bottles swapped in the morning and afternoon. Sugar and pure water consumption were recorded, and the sugar consumption rate was calculated.

[0104] Sugar water consumption rate = sugar water consumption / (sugar water consumption + pure water consumption)

[0105] 3.2 Determination of TNF-α, IL-1β, and INF-γ Levels

[0106] ELISA was used to measure the levels of IL-1β, INF-γ, and TNF-α in brain tissue homogenates. Related studies have shown that under stress, the levels of inflammatory factors in brain tissue homogenates of depression models are significantly elevated, but these levels return to normal after treatment with antidepressants. After behavioral testing, rats were anesthetized with an intraperitoneal injection of 1% pentobarbital, and the brains were removed by decapitation. A 10% brain tissue homogenate was prepared using pre-cooled 0.9% sodium chloride solution. A portion of the homogenate was centrifuged at a radius of 13.5 cm and 2500 rpm for 10 minutes, and the supernatant was collected. The levels of IL-1β, INF-γ, and TNF-α in brain tissue homogenates were determined according to the ELISA assay kit instructions.

[0107] 3.3 Determination of 5-HT and Dopamine Levels in Rat Cortex and Hippocampus

[0108] Literature suggests that low serotonin and dopamine levels are partially due to depression and anxiety, while a moderate increase in serotonin and dopamine is beneficial for maintaining mental health. After orbital blood collection, rats were sacrificed by cervical dislocation. The cortex and hippocampus were quickly dissected, weighed, and rapidly frozen in liquid nitrogen before being stored in a -80°C freezer. Appropriate amounts of cortical and hippocampal tissue were each minced and weighed. Ten times the volume of normal saline was added, and the mixture was homogenized using a tissue disruptor at low temperature. The mixture was centrifuged at 8000 rpm for 10 minutes at 4°C. The supernatant was collected and the levels of serotonin and dopamine in the rat cortex and hippocampus were measured according to the ELISA kit instructions.

[0109] 3.4 Statistical analysis

[0110] SPSS 22.0 software was used to perform statistical analysis on the data. The data were compared between multiple groups using one-way analysis of variance, and between two groups using independent sample T-test. P < 0.05 was considered statistically significant.

[0111] 4. Results and Conclusions

[0112] 4.1 Behavioral status of rats

[0113] The results of the body weight increase of rats in each group showed that after 21 days of administration, the differences between the model group and the blank group and the moclobemide tablet group, the Yangxinshi tablet group, the three dose groups of Example 1 (high, medium, and low), Example 2 group, and Example 3 group were statistically significant (P < 0.05), indicating that the administration of each group can improve the symptoms of loss of appetite and weight loss in depression model rats.

[0114] Table 2 Effect of 21-day drug administration on the body weight gain of rats ( n=10)

[0115]

[0116] Note: Compared with the blank group, *P<0.01; compared with the model group, # P < 0.01, @ P<0.05.

[0117] 4.2 Changes in sugar water consumption

[0118] The results of sugar consumption rate of rats in each group showed that after 21 days of administration, the differences between the model group and the blank group and the moclobemide tablet group, the Yangxinshi tablet group, the three dose groups of Example 1 (high, medium, and low), Example 2 group, and Example 3 group were statistically significant (P < 0.05), indicating that the administration of each group can improve the anhedonia symptoms of depression model rats.

[0119] Table 2 Sugar consumption rate of rats after 21 days of drug administration ( n=10)

[0120]

[0121] Note: Compared with the blank group, *P<0.01; compared with the model group, # P<0.01.

[0122] 4.3 Levels of TNF-α, IL-1β, and INF-γ in rat brain tissue homogenates

[0123] The results of the content of TNF-α, IL-1β, and INF-γ in the brain tissue homogenates of rats in each group showed that after 21 days of administration, the model group and the blank group were compared with the moclobemide tablet group, the Yangxinshi tablet group, the three dose groups of Example 1 (high, medium, and low), Example 2 group, and Example 3 group, respectively, with statistically significant differences (P < 0.05). This shows that the administration of each group can reduce the content of inflammatory factors.

[0124] Table 3 TNF-α, IL-1β, and INF-γ contents in rat brain tissue homogenate after 21 days of administration ( n=10)

[0125]

[0126] Note: Compared with the blank group, *P<0.01; compared with the model group, ％ P<0.01.

[0127] 4.4 Levels of 5-HT and Dopamine in Rat Cortex and Hippocampus

[0128] The results of the 5-HT and dopamine levels in the cortex and hippocampus of rats in each group showed that after 21 days of administration, the model group and the blank group were compared with the moclobemide tablet group, the Yangxinshi tablet group, the three dose groups of Example 1 (high, medium, and low), Example 2 group, and Example 3 group, respectively, with statistically significant differences (P < 0.05). This shows that the administration of each group can increase the 5-HT and dopamine levels.

[0129] Table 3 5-HT and dopamine contents in rat cortex and hippocampus after 21 days of administration ( n=10)

[0130]

[0131] Note: Compared with the blank group, *P<0.01, # P < 0.05;

[0132] Compared with the model group, ％ P < 0.01, @ P<0.05.

[0133] In summary, according to the above pharmacodynamic experimental results, the Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, improve the symptoms of loss of interest in depression model rats, effectively alleviate the increase in inflammatory factor levels (TNF-α, IL-1β, INF-γ) caused by depression, and significantly increase the levels of serotonin and dopamine in the rat cortex and hippocampus, indicating that the Chinese medicine composition of the present invention can effectively treat depression.

Claims

1. Use of a Chinese medicine composition in preparing a drug for treating depression, the Chinese medicine composition being prepared from the following raw materials: 150-200 parts by weight of Astragalus root; 60-120 parts by weight of Codonopsis pilosula; 40-90 parts by weight of Ophiopogon japonicus 35-80 parts by weight of Polygonum multiflorum, 35-80 parts by weight of Epimedium, 120-170 parts by weight of Pueraria root 35-80 parts by weight of Chinese Angelica sinensis, 80-120 parts by weight of Salvia miltiorrhiza, 35-80 parts by weight of Gleditsia sinensis 60-120 parts by weight of seaweed, 60-120 parts by weight of kelp, 60-120 parts by weight of oyster, 5-50 parts by weight of Citrus aurantium.

2. The use according to claim 1, characterized in that The depression is endogenous depression, reactive depression, latent depression, secondary depression, psychotic depression, manic depression, postpartum depression, menopausal depression, senile depression or seasonal depression.

3. The use according to claim 1, characterized in that The depression is caused by one or more of biological factors, psychological factors, drug factors, environmental factors, stress factors, and physiological factors.

4. The use according to claim 3, characterized in that The biological factors are genetic, neurochemical, neuroendocrine or neural regeneration.

5. The use according to claim 1, characterized in that The Chinese medicine composition is prepared from the following raw materials: 173 parts by weight of Astragalus root, 93 parts by weight of Codonopsis pilosula, 67 parts by weight of Ophiopogon japonicus, 53 parts by weight of Polygonum multiflorum 53 parts by weight of Epimedium, 147 parts by weight of Puerariae Radix, 53 parts by weight of Angelicae Sinensis, 100 parts by weight of Salviae Miltiorrhiza 53 parts by weight of Gleditsia spinosa, 93 parts by weight of seaweed, 93 parts by weight of kelp, 93 parts by weight of oyster, 27 parts by weight of Citrus aurantium.

6. The use according to any one of claims 1 to 5, wherein the Chinese medicine composition is prepared into a preparation with pharmaceutically acceptable excipients.

7. The use according to claim 6, characterized in that The preparation is oral liquid, granules, tablets, capsules, pills, powders, syrups, microcapsules or pastes.

Images